<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00432406</url>
  </required_header>
  <id_info>
    <org_study_id>PSA-2006-002</org_study_id>
    <nct_id>NCT00432406</nct_id>
  </id_info>
  <brief_title>Tumor Necrosis Factors (TNF)-α Blockade for Psoriatic Arthritis</brief_title>
  <official_title>TNF-α Blockade for Psoriatic Arthritis - A Clinical and MRI Study, and the Effects on Cytokine and Cardiovascular Risk Profile</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is:&#xD;
&#xD;
        -  To elucidate the immunomodulating properties of anti-TNF-α therapy in patients with&#xD;
           psoriatic arthritis (PsA).&#xD;
&#xD;
        -  To ascertain whether magnetic resonance imaging (MRI) is a sensitive tool in measuring&#xD;
           early response after therapy with anti-TNF-α in the PsA wrist using the Outcome Measures&#xD;
           in Rheumatoid Arthritis Clinical Trials (OMERACT) guidelines for rheumatoid arthritis&#xD;
           (RA).&#xD;
&#xD;
        -  To assess whether the lipid and other cardiovascular risk profiles would improve after&#xD;
           anti-TNF-α therapy in patients with PsA.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was a 12-week, open-label trial of anti-TNF therapy in 20 consecutive patients&#xD;
      (Group 1). Another 20 consecutive patients with active disease whom have met the exclusion&#xD;
      criteria, or were unwilling to start anti-TNF therapy for fear of toxicity would be recruited&#xD;
      as control patients (Group 2). 20 healthy controls were recruited for comparison of the&#xD;
      metabolic risk factors (Group 3). Study visits for groups 1 and 2 were conducted at baseline,&#xD;
      weeks 2 and 6, and then week 12.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the degree of inflammation as reflected by the MRI score, cytokines and chemokine levels</measure>
    <time_frame>week 52</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in the cardiovascular risk factor levels which are directly mediated by TNF-α</measure>
    <time_frame>week 52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients who can achieve ACR 20</measure>
    <time_frame>week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of clinical parameter, inflammatory markers and MRI findings</measure>
    <time_frame>week 52</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>infliximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>etanercept</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <description>Infliximab 5 mg/kg given at day 1, week 2, week 6</description>
    <arm_group_label>1</arm_group_label>
    <other_name>remicade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>Etanercept 25 mg twice weekly</description>
    <arm_group_label>2</arm_group_label>
    <other_name>enbrel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 or above&#xD;
&#xD;
          -  PsA with active disease despite treatment with non-steroidal anti-inflammatory drug&#xD;
             (NSAID)&#xD;
&#xD;
          -  3 or more swollen and tender joints&#xD;
&#xD;
          -  Inadequate response after 4 weeks of, or intolerance to nonsteroidal anti-inflammatory&#xD;
             drug therapy.&#xD;
&#xD;
          -  Methotrexate (MTX) is allowed during the study only if it has been taken for at least&#xD;
             3 months previously, with the dosage stable for at least 4 weeks prior to the baseline&#xD;
             visit.&#xD;
&#xD;
          -  Prednisone ≤ 10 mg/day and/or nonsteroidal anti-inflammatory drugs must have been&#xD;
             taken at stable dosage for at least 2 weeks before entering the trial.&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Little or no ability for self-care&#xD;
&#xD;
          -  Used a DMARD other than methotrexate or received intra-articular, intramuscular, or&#xD;
             intravenous corticosteroids in the 4 weeks before screening.&#xD;
&#xD;
          -  Topical vitamin A (Neotigason CR) or D analog preparations (Daivonex CR), and&#xD;
             anthralin for psoriasis within 2 weeks of baseline.&#xD;
&#xD;
          -  Concurrent treatment with MTX at dosages &gt; 15 mg/week and/or corticosteroids in a&#xD;
             prednisone-equivalent dosage of &gt; 10 mg/day.&#xD;
&#xD;
          -  Prior anti-TNF therapy at any time.&#xD;
&#xD;
          -  Infected joint prosthesis during the previous 5 years.&#xD;
&#xD;
          -  Serious infections, such as hepatitis, pneumonia, pyelonephritis in the previous 3&#xD;
             months.&#xD;
&#xD;
          -  Any chronic infectious disease such as renal infection, chest infection with&#xD;
             bronchiectasis or sinusitis.&#xD;
&#xD;
          -  Active tuberculosis requiring treatment within the previous 3 years.&#xD;
&#xD;
          -  Opportunistic infections such as herpes zoster within the previous 2 months.&#xD;
&#xD;
          -  Any evidence of active cytomegalovirus; active Pneumocystis carinii; or drug-resistant&#xD;
             atypical mycobacterial infection.&#xD;
&#xD;
          -  Known hypersensitivity to murine proteins&#xD;
&#xD;
          -  Current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic,&#xD;
             haematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, or&#xD;
             cerebral disease.&#xD;
&#xD;
          -  A history of lymphoproliferative disease including lymphoma or signs suggestive of&#xD;
             disease, such as lymphadenopathy of unusual size or location (ie, lymph nodes in the&#xD;
             posterior triangle of the neck, infraclavicular epitrochlear, or periaortic areas);&#xD;
             splenomegaly.&#xD;
&#xD;
          -  Any known malignant disease except basal cell carcinoma currently or in the past 5&#xD;
             years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edmund K Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <study_first_submitted>February 6, 2007</study_first_submitted>
  <study_first_submitted_qc>February 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2007</study_first_posted>
  <last_update_submitted>March 10, 2009</last_update_submitted>
  <last_update_submitted_qc>March 10, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2009</last_update_posted>
  <responsible_party>
    <name_title>Edumun K Li, MD</name_title>
    <organization>The Chinese University of Hong Kong</organization>
  </responsible_party>
  <keyword>Psoriatic Arthritis</keyword>
  <keyword>TNF-α</keyword>
  <keyword>Cardiovascular risk</keyword>
  <keyword>Immunomodulatory activities</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

